Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study

Ruben R. De With, Michiet Rienstra, Marcelle D. Smit, Bob Weijs, Victor W. Zwartkruis, Anne H. Hobbelt, Marco Atings, Jan G. P. Tijssen, Johan Brugemann, Bastiaan Geelhoed, Hans L. Hillege, Raymond Tukkie, Martin E. Hemels, Robert G. Tieleman, Adetita Ranchor, Dirk J. Van Veldhuisen, Harry J. G. M. Crijns, Isabelle C. Van Gelder*, RACE 3 Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)563-571
Number of pages9
JournalEP Europace
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Atrial fibrillation
  • Quality of life
  • Risk factor
  • Targeted therapy
  • Randomized clinical trial
  • RHYTHM CONTROL
  • TRIAL
  • MANAGEMENT

Cite this

De With, R. R., Rienstra, M., Smit, M. D., Weijs, B., Zwartkruis, V. W., Hobbelt, A. H., Atings, M., Tijssen, J. G. P., Brugemann, J., Geelhoed, B., Hillege, H. L., Tukkie, R., Hemels, M. E., Tieleman, R. G., Ranchor, A., Van Veldhuisen, D. J., Crijns, H. J. G. M., Van Gelder, I. C., & RACE 3 Investigators (2019). Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. EP Europace, 21(4), 563-571. https://doi.org/10.1093/europace/euy311